Abstract

To investigate the prevalence of metabolic syndrome (MS) in the patients with coronary heart disease (CHD) in China. The clinical data, including anthropometric data, case record form (CRF), clinical examination, etc. of all CHD patients hospitalized from 1 Jun 2005 to 31 Sep 2005 in the department of cardiology of 52 hospitals in 7 northern, middle, and southern cities in China. A total of 3513 CHD patients, 2341 males and 1172 females, aged 23 approximately 99, were recruited. The prevalence of MS was 30.4% among the 3513 CHD patients, 27.4% among the males and 36.4% among the females. The prevalence of MS among the CHD patients in the northern cities was 36.5%, significantly higher than those in the middle and southern cites (25.% and 25.1% respectively, chi(2) = 50.252, P < 0.001), with a trend to gradually decrease from north to south. The prevalence of MS among the CHD patients receiving acute admission was 28.8%, not significantly different from that receiving scheduled admission (31.2%, P = 0.139). There was a clear age-related increase in the prevalence of MS (chi(2) = 23.625, P < 0.001). The prevalence of MS of the males aged < 60 was higher than that of the females aged < 60; and the prevalence of MS of the females aged > 60 was higher than that of the females aged > 60. The prevalence of MS in CHD patients is rather high in China. It is important to screen for MS in patients with high risk for new vascular incidents.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.